Vesnik 03/2004) e izvrshena privatizatsija na aptekite,a galenskata laboratorija do deneska e vo sostav na bolnichkataapteka pri JZU Opshta bolnitsa Okhrid.Galenskata laboratorija pri bolnichkata apteka vo JZU Opshtabolnitsa Okhrid, i pokraj nastanatite promeni vo titularot, vokontinuitet proizveduva magistralni lekovi za potrebite naaptekite i galenski preparati za potrebite na bolnitsata i drugitezdravstveni ustanovi.Vo ovoj trud imame za tsel da ja prosledime potroshuvachkata na108PETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOMakedonski farmatsevtski bilten 57 (dodatok), 2011FARMAKOEKONOMIJA / SOTsIJALNAFARMATsIJA/ FARMAKOINFORMATIKA poster prezentatsiimagistralnite lekovi vo galenskata laboratorija vo Okhrid voperiodot 2001-2010 godina po broj na propishani retsepti, sostav,dozazhna forma, kako i vlijanieto na promenite vo regulativata ifarmatsevtskiot pazar vrz obemot na proizvodstvo.Od napravenata analiza mozhe da se zakluchi deka promenata vozakonskite reshenija i koristenjeto na poshirok asortiman nagotovi lekovi, kako i kokurentsijata od novootvorenite galenskilaboratorii doveduvaat do pad na proizvodstvoto na magistralnilekovi vo galenskata laboratorija vo Okhrid.cost - effectiveness analysis ofantimicrobial Drugs useD in thetreatment of acute exacerbationsof chronic bronchitis anD chronicobstructive pulmonary DiseaseAcevski Stevce1, Sterjev Zoran2, Suturkova Ljubica2,Zareski Rubin21PharmaSwiss, Republic of Macedonia 2University "St. Cyril andMethodius", Faculty of Pharmacy Skopje, Republic of MacedoniaobjectiveCost-effective analysis of most commonly used antimicrobial drugsfor treatment of acute exacerbations of chronic bronchitis andchronic obstructive pulmonary disease (COPD).introDuctionCOPD is a lung disease characterized by chronic obstruction of lung air-flow that interferes with normal breathing and is not fully reversible.Acute exacerbations of COPD are an abrupt increase in symptoms ofshortness of breath and/or wheezing, often associated with increase inproduction of purulent sputum. Hospitalization may be required if thesymptoms are severe. If symptoms are milder, one may choose to betreated as an outpatient.1 Among other treatment agents, antibioticsare often used to treat bacterial infections. Approximately 50% of acuteexacerbations are due primarily to the bacteria Streptococcus pneumo-nia, Haemophilus influenzae and Moraxella catarrhalis.2 Five antibioticregimens were used in the treatment of acute exacerbation of chronicpulmonary disease on outpatients. Data showed close range of effec-tiveness, we carry out cost effectiveness analysis for antibiotic regimens.material anD methoDsData for the efficacy and tolerability of five most commonly used an-tibiotics for the treatment of acute exacerbations of chronic bron-chitis and COPD was retrieved from published study.3 Results for theefficacy and tolerability were in correlation with six published studies,for antibiotic treatment in COPD. Antibiotics included were: amoxi-cillin/clavulanic acid (AMO/CL) 875 mg/125 mg twice daily, cefuroxime(CEFUR) 250 mg twice daily, cefixime (CEFIX) 400 mg once daily, clar-ithromycin (CLARI) 500 mg twice daily and ciprofloxacin (CIPRO) 500mg twice daily. Prices for the used antibiotics were obtained from Min-istry of Health; Bureau for medicines.4 Cost-effectiveness analysis wasconducted based on collected data.resultsEffectiveness of treatment showed similar clinical success in the fiveantibiotic groups from 68.9% with AMO/CL, CLARI 72.7%, CEFIX 73.5%,CEFUR 75% and CIPRO 77.1%.Figure 1: Success of therapy of acute exacerbations of COPD withamoxicillin/clavulonic acid, clarithromycin, cefixime, cefuroxime andciprofloxacinAccording to the data for mean time to resolution of the symptoms orreturn to the baseline severity results showed that AMO/CL patientsneed 6.8 days, 6.1 days for CEFUR, 6.4 days for CEFIX, 6.4 days withCLARI and 6.5 days for CIPRO patients.Figure 2: Mean time to relief of the symptoms in the five groups: amox-icillin/clavulonic acid, cefuroxime, cefixime, clarithromycin andciprofloxacinCost-effective ratio (CER) analysis showed that CEFUR and CIPRO aremore cost-effective than other three antibiotics (CEFUR ICER = - 670and ICER = - 233 for CIPRO).Table 1. Incremental cost effectiveness ratio (ICER) for amoxicillin/clavu-lonic acid (AMO/CL), clarithromicin (CLARI), cefixime (CEFIX), cefurox-ime (CEFUR) and ciprofloxacin (CIPRO) used in the treatment of acuteexacerbations of COPDAbbreviations: E - Average effectiveness, C - Cost of treatment,  C -difference of cost of treatment,  E - difference of effectiveness, ICER- incremental cost effectiveness ratioICER analysis showed dominant cost-effectiveness of CIPRO over theother four antibiotics.109fifth congress of pharmacy of maceDonia with international participationMacedonian Pharmaceutical Bulletin 57 (suppl), 2011PHARMACOECONOMY / SOCIAL PHARMACY/ PHARMACOINFORMATICS poster presentationsTable 2. Incremental cost effectiveness ratio (ICER) for clarithromicin(CLARI) and ciprofloxacin (CIPRO) used in the treatment of acute ex-acerbations of COPDAbbreviations: E - average effectiveness, C - cost of treatment,  C -diference of cost of treatment,  E - diference of effectiveness, ICER- incremental cost effectiveness ratioconclusionCost-effectiveness analysis of five antibiotic regimens most commonlyused for treatment of acute exacerbations of COPD showed signifi-cant advantage of cost savings and efficacy when using CIPRO overthe other four antibiotic regimens.referencesWorld Health Organisation - Definitions of COPD - http://www.who.int/respira-tory/copd/ (last accessed 21.04.2011)Ball P, Chodosh S, Grossman R, et al. Causes, epidemiology and treatment ofbronchial infections. Infect Med.2000;17:186-198.Minov J, Karadzinska-Bislimovska J, Petrova T, et al. Efficacy and Tolerability of Vari-ous Antimicrobial Regimens In the Treatment of Exacerbations of Chronic Bronchi-tis and Chronic Obstructive Pulmonary Disease in Outpatients : Macedonian Journalof Medical Sciences, 2009 Jun 15: 2(2):115 - 120.Bureau for medicines, Ministry of Health, published on official web page www.re-glek.com.mk; (last accessed on 21.04.2011)TROshOK-EFIKASNOST ANAlIzANA ANTIbIOTITsI KORISTENIzA TRETMAN NA AKUTNAEKzATsERbATsIJA OD khRONIChENbRONkhITIS I khRONIChNAObSTRUKTIVNA bElODRObNA bOlEST(khObb)Atsevski Stevche1, Sterjev Zoran2,Shuturkova Ljubitsa2, Zareski Rubin21Farmasvis, Republika Makedonija 2Univerzitet ,,Sv.Kirili Metodij", Farmatsevtski fakultet, Skopje, Republika MakedonijaTsElTroshok-efikasnost analiza na najchesto koristenite antibiotitsiza tretman na akutni ekzartsebatsii na khronichen bronkhitis ikhronichna obstruktivna belodrobna bolest (KhOBB).VOVEDKhOBB e bolest na belite drobovi, koja se odlikuva so khronichnaobstruktsija na dishenjeto, koe go otezhnuva normalnoto dishenje,chesto e nepovratno. Akutni ekzatserbatsii na KhOBB se naglo vloshu-vanje na simptomite od nedostatok na zdiv i/ili teshko dishenje,chesto pridruzheno so zgolemena sekretsija na purulenten sputum.Khospitalizatsija e potrebna pri poteshki simptomi, a akosimptomite se polesni patsientot e ambulantski.1 Pokraj drugitepreparati, antibiotitsi chesto se koristat za tretiranje na bakte-riskata infektsija. Okolu 50 % od akutnite ekzatserbatsii se pre-dizvikani od Streptococcus pneumonia, Haemophilus influenzae iMoraxella catarrhalis.2 Pet antibiotitsi bea koristeni za tretmanna akutni ekzatserbatsii na KhOBB kaj ambulantski patsienti. Podato-tsite pokazhaa tesen opseg na efikasnost, izvrshivme troshok-efi-kasnost analiza.MATERIJAl I METODPodatotsite za efikasnosta i podnoslivosta na antibiotitsitekoristeni za tretman na akutna ekzatserbatsija na KhOBB beadobieni od objavena studija.3 Rezultatite se vo pozitivnakorelatsija so shest objaveni studii, za upotreba na antibiotitsipri KhOBB. Koristeni bea: amoksitsilin/klavulonska kiselina(AMO/KL) 875 mg/125 mg dva pati na den, tsefuroksim (TsEFUR) 250mg dva pati na den, tsefiksim (TsEFIK) 400 mg ednash dnevno, kla-ritromitsin (KLARI) 500 mg dva pati na den i tsiprofloksatsin(TsIPRO) 500 mg dva pati na den. Tsenite za koristenite antibioti-tsi bea dobieni od ofitsijalniot tsenovnik za edinstveni tseni naBiroto za lekovi, pri Ministerstvoto za zdravstvo.4 Troshok-efi-kasnost analiza beshe izvrshena so sobranite podatotsi.REzUlTATIEfikasnosta na tretmanot pokazha bliski granitsi na uspekh 68.9%za AMO/KL, KLARI 72.7%, TsEFIK 73.5%, TsEFUR 75% i TsIPRO77.1%.Slika 1: Efikasnost na antibiotska terapija na akutni ekzatser-batsii na KhOBBSpored podatotsite prosechno vremetraenje na terapijata se dvizhe-she od 6.8 dena za AMO/KL, 6.1 za TsEFUR, 6.4 za TsEFIK, 6.4 za KLARIi 6.5 dena za TsIPRO.Slika 2. Prosechno vremetraenje na antibiotska terapija na akutniekzatserbatsii na KhOBB110PETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOMakedonski farmatsevtski bilten 57 (dodatok), 2011FARMAKOEKONOMIJA / SOTsIJALNAFARMATsIJA/ FARMAKOINFORMATIKA poster prezentatsiiTroshok-efikasnost analizata pokazha deka TsEFUR i TsIPRO sepovekje troshok-efikasni od drugite tri antibiotitsi. (TsEFURITsER = - 670 i ITsER = - 233 za TsIPRO).Tabela 1 Rastechki troshok-efikasnost odnos (ITsER) za amoksitsi-lin/klavulonska (AMO/KL), klaritromitsin (KLARI), tsefiksim (TsEFIK),tsefuroksim (TsEFUR) i tsiprofloksatsin (TsIPRO) koristeni za tretmanna akutni ekzatserbatsii na KhOBBKratenki: E - Prosechna efikasnost, T - Troshok na tretmanot,  T -razlika na troshok na tretmanot,  E - razlika na efikasnost natretmanot, ITsER - rastechki troshok-efikasnost odnosITsER pokazha dominantna troshok-efikasnost na TsIPRO vo odnosna drugite chetiri antibiotitsi.Tabela 2. Rastechki troshok-efikasnost odnos (ITsER) za klaritro-mitsin (KLARI) i tsiprofloksatsin (TsIPRO) koristeni za tretman naanutni ekzatserbatsii na KhOBBKratenki: E - Prosechna efikasnost, T - Troshok na tretmanot,  T -razlika na troshok na tretmanot,  E - razlika na efikasnost natretmanot, ITsER - rastechki troshok-efikasnost odnoszAKlUChOKTroshok-efikasnost analizata na pet antibiotitsi najchesto koristeniza tretman na akutni ekzatserbatsii na KhOBB pokazhaa znachitelnazashteda i podobra efikasnost pri koristenje na TsIPRO vo odnosna drugite chetiri antibiotitsi.KORISTENA lITERATURAWorld Health Organisation - Definitions of COPD - http://www.who.int/respira-tory/copd/ (last accessed 21.04.2011)Ball P, Chodosh S, Grossman R, et al. Causes, epidemiology and treatment ofbronchial infections. Infect Med.2000;17:186-198.Minov J, Karadzinska-Bislimovska J, Petrova T, et al. Efficacy and Tolerability of Vari-ous Antimicrobial Regimens In the Treatment of Exacerbations of Chronic Bronchi-tis and Chronic Obstructive Pulmonary Disease in Outpatients : MacedonianJournal of Medical Sciences, 2009 Jun 15: 2(2):115 - 120.Bureau for medicines, Ministry of Health, published on official web page www.re-glek.com.mk; (last accessed on 21.04.2011)pharmaeconomic analysis ofrivaroxaban for prevention of vtein patients unDergoing elective hipanD knee replacement surgerySterjev.Z1, Petrovska Angelovska.A2,Gavazova Kozareva.K21University "St.Cyril and Methodius" Faculty of Pharmacy Skopje,Republic of Macedonia2Bayer d.o.o. - Representative Office SkopjeintroDuctionRivaroxaban is a new oral highly selective, direct inhibitor of coagu-lation factor Xa. It is indicated in the prevention of venous throm-boembolism (VTE) in adult patients undergoing major lower limboperations.objectiveDetermining the cost-effectiveness of rivaroxaban vs enoxaparin inthromboprophylaxis after complete hip and knee replacement surgeryin Macedonia.materials anD methoDsTo realize the goal, pharmaeconomic cost-effectiveness study is ap-plied. Required efficiency data was taken from four phase III studies(RECORD 1, 2, 3 and 4) conducted in patients with elective hip andknee replacement surgery. These cost data was obtained from publicdata available from DRG of the Health Insurance Fund of Macedoniaand the official data for the price of drugs published on the website ofthe Ministry of Health of the Republic of MacedoniaresultsImplemented pharmaeconomic analysis suggests a minimum reduc-tion of material costs by around 5900 denars per patient if rivroxabanis used in Republic of Macedonia for the prevention of venous throm-boembolism (VTE) in adult patients undergoing major lower limb op-erations. Unfortunately, in Macedonia there are no adequate data onthe effectiveness of treatment with rivaroxaban and other productsfor prevention of venous thromboembolism (VTE), so ICER as a realpharmaeconomic indicator cannot be calculated.